DAVITA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147.1 USD | -0.01% |
|
+6.19% | +40.44% |
| May. 24 | FMC, Fresenius and Davita rise after Ozempic news | DP |
| May. 15 | Truist Securities Raises Price Target on DaVita to $150 From $135, Keeps Hold Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- One of the major weak points of the company is its financial situation.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +40.44% | 12.9B | B- | ||
| +25.52% | 88.99B | C+ | ||
| -24.52% | 74.82B | B- | ||
| -5.56% | 25.03B | C+ | ||
| +4.31% | 17.88B | A- | ||
| -14.25% | 16.43B | B | ||
| +2.97% | 15.77B | A- | ||
| +70.11% | 13.09B | C- | ||
| +79.20% | 13.21B | C+ | ||
| +24.51% | 12.7B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- DVA Stock
- Ratings DaVita Inc.
